IMV Inc. Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- IMV Inc.'s estimated annual revenue is currently $22.9M per year.
- IMV Inc.'s estimated revenue per employee is $155,000
- IMV Inc. has 148 Employees.
- IMV Inc. grew their employee count by 10% last year.
- IMV Inc. currently has 1 job openings.
What Is IMV Inc.?
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company?s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. For more information, please connect at: www.imv-inc.comkeywords:N/A